Tonix Pharmaceuticals stock halted ahead of FDA approval news
Acumen Pharmaceuticals, trading under the ticker ABOS, has seen its stock price touch a 52-week low, reaching a price level of $1.1 USD. This significant downturn reflects a challenging period for the company, with the stock experiencing a precipitous decline of -73.34% over the past year. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 6.46, though it’s quickly burning through cash. Analyst price targets range from $4 to $11, suggesting potential upside despite current market sentiment. Investors have been closely monitoring Acumen’s performance, as the company navigates through a landscape marked by heightened volatility and shifting market dynamics. The 52-week low serves as a critical indicator of the stock’s current trajectory and is a focal point for discussions about the company’s future prospects and potential recovery strategies. With a market capitalization of just $65.42 million, InvestingPro analysis suggests the stock is slightly undervalued, with 12 additional exclusive insights available to subscribers through the comprehensive Pro Research Report.
In other recent news, Acumen Pharmaceuticals reported a net loss of $102.3 million for 2024, primarily due to increased research and development expenses associated with the ALTITUDE AD trial. Despite the financial loss, the company maintains a strong cash position with $231.5 million in cash and marketable securities, which is expected to support operations into 2027. The company has completed enrollment for the Phase II ALTITUDE AD study with 542 participants, focusing on its Alzheimer’s treatment, Sibronotug, which targets toxic A-beta oligomers.
H.C. Wainwright analyst Andrew S. Fein recently adjusted the price target for Acumen, reducing it to $11 from $15, while maintaining a Buy rating. The adjustment was due to a reevaluation of the company’s operational expenditure assumptions. Fein highlighted the completion of enrollment for the ALTITUDE AD clinical trial and the anticipation for topline data expected around the end of 2026. Acumen has also completed a study on a subcutaneous formulation of sabirnetug in healthy volunteers, which showed a decent safety profile despite mild injection site reactions.
The company is optimistic about its future, with top-line results from the ALTITUDE AD study expected in late 2026. Acumen is also engaged in developing a subcutaneous formulation of Sibronotug and ongoing biomarker research. The focus remains on the Integrated Alzheimer’s Disease Rating Scale (IDRIS) as the primary endpoint for its trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.